Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Operating Expenses (2016 - 2026)

Cytosorbents filings provide 15 years of Operating Expenses readings, the most recent being $11.2 million for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 15.95% to $11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.2 million, a 0.24% change, with the full-year FY2025 number at $41.2 million, changed 0.24% from a year prior.
  • Operating Expenses hit $11.2 million in Q4 2025 for Cytosorbents, up from $9.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $17.2 million in Q4 2021 to a low of $9.5 million in Q3 2025.
  • Median Operating Expenses over the past 5 years was $12.4 million (2022), compared with a mean of $12.2 million.
  • Biggest five-year swings in Operating Expenses: surged 44.66% in 2021 and later tumbled 34.1% in 2024.
  • Cytosorbents' Operating Expenses stood at $17.2 million in 2021, then dropped by 29.66% to $12.1 million in 2022, then grew by 20.88% to $14.6 million in 2023, then tumbled by 34.1% to $9.6 million in 2024, then rose by 15.95% to $11.2 million in 2025.
  • The last three reported values for Operating Expenses were $11.2 million (Q4 2025), $9.5 million (Q3 2025), and $10.4 million (Q2 2025) per Business Quant data.